Anti-programmed death receptor 1 immunotherapy in melanoma: Rationale, evidence and clinical potential

Therapeutic Advances in Medical Oncology

Volumn 7, Issue 1, 2015, Pages 12-21

  Freeman Keller, Morganna ^a   Weber, Jeffrey S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

immunotherapy; melanoma; programmed death receptor 1; programmed death receptor ligand

Indexed keywords

ANTI PROGRAMMED DEATH RECEPTOR 1; ANTINEOPLASTIC AGENT; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CELL INTERACTION; HUMAN; MELANOMA; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE;

EID: 84918545182     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834014551747     Document Type: Review

References (71)

1. Amin A. Plimack E. Infante J. Ernstoff M. Rini B. McDermott D. et al. (2014) Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).J Clin Oncol 32(5 Suppl.): abstract 5010.
2. Benson D. Bakan C. Mishra A. Hofmeister C. Efebera Y. Becknell B. et al. (2010) The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116: 2286–2294.
3. Berger R. Rotem-Yehudar R. Slama G. Landes S. Kneller A. Leiba M. et al. (2008) Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14: 3044–3051.
4. Blank C. Brown I. Peterson A. Spiotto M. Iwai Y. Honjo T. et al. (2004) PD-L1/B7-H1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 64: 1140–1145.
5. Blazar B. Carreno B. Panoskaltsis-Mortari A. Carter L. Iwai Y. Yagita H. et al. (2003) Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma dependent mechanism. J Immunol 171: 1272–1277.
6. Bowers N. Helton E. Huijbregts R. Goepfert P. Heath S. Zdenek H. (2014) Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway. PLoS Pathogens 10: e1003993.
7. Brahmer J. Drake C. Wollner I. Powderly J. Picus J. Sharfman W. et al. (2010) Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167–3175.
8. Brahmer J. Tykodi S. Chow L. Hwu W. Topalian S. Hwu P. et al. (2012) Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455–2465.
9. Brayer J. Fishman M. (2014) Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab. J Immunother 37: 187–191.
10. Brusa D. Massi D. Merelli B. Ciano M. Audrito V. Serra S. et al. (2014) PD-L1 expression identifies a subpopulation of melanoma cells characterized by enhanced invasiveness and aggressiveness. Poster presented at American Association for Cancer Research 2014 Annual Meeting, 9 April, San Diego, CA, USA: abstract: CT5604.
11. Carter L. Fouser L. Jussif J. Fitz L. Deng B. Wood C. et al. (2002) PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. Eur J Immunol 32: 634–643.
12. Curiel T. Coukos G. Zou L. Alvarez X. Cheng P. Mottram P. et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942–949.
13. Curiel T. Wei S. Dong H. Alvarez X. Cheng P. Mottram P. et al. (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9: 562–567.
14. Daud A. Hamid O. Ribas A. Hodi F. Hwu W. Kefford R. et al. (2014) Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma: correlation of tumor PD-L1 expression with outcome. Poster presented at American Association for Cancer Research 2014 Annual Meeting, 9 April, San Diego, CA, USA: abstract: CT104.
15. Dong H. Strome S. Salomao D. Tamura H. Hirano F. Flies D. et al. (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793–800.
16. Flaherty K. Puzanov I. Kim K. Ribas A. McArthur G. Sosman J. et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809–819.
17. Freeman G. Long A. Iwai Y. Bourque K. Chernova T. Nishimura H. et al. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B 7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027–1034.
18. Fridman W. Pages F. Sautes-Fridman C. Galon J. (2012)The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12: 298–306.
19. Gabrilovich D. Nagaraj S. (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162–174.
20. Garbe C. Peris K. Hauschild A. Saiag P. Middleton M. Spatz A. et al. (2010) Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 46: 270–283.
21. Garon E. Balmanoukian A. Hamid O. Hui R. Gandhi L. Leighl N. et al. (2014) MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity. Clin Cancer Res 20: abstract A20.
22. Gettinger S. Shepherd F. Antonia S. Brahmer J. Man Chow L. Juergens R. et al. (2014) First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin Oncol 32 (5 Suppl.): abstract 8024.
23. Grosso J. Horak C. Inzunza D. Cardona D. Simon J. Gupta A. et al. (2013) Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 31: abstract CRA3016.
24. Hamanishi J. Mandai M. Ikeda T. Minami M. Kawaguchi A. Matsumura N. (2014) Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. J Clin Oncol 32(5 Suppl.): abstract 5511.
25. Hamid O. Robert C. Daud A. Hodi F. Hwu W. Kefford R. et al. (2013 a) Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma. N Engl J Med 369: 134–144.
26. Hamid O. Sosman J. Lawrence D. Sullivan R. Ibrahim N. Kluger H. et al. (2013 b) Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma. J Clin Oncol 31: abstract CRA9010.
27. He Y. Zhang G. Wang X. Zhang H. Yuan Y. Li D. et al. (2004) Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J Immunol 173: 4919–4928.
28. Hino R. Kabashima K. Kato Y. Yagi H. Nakamura M. Honjo T. et al. (2010) Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116: 1757–1766.
29. Hirano F. Kaneko K. Tamura H. Dong H. Wang S. Ichikawa M. et al. (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65: 1089–1096.
30. Hodi F. O'Day S. McDermott D. Weber R. Sosman J. Haanen J. et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711–723.
31. Hodi F. Sznol M. Kluger H. McDermott D. Carvajal R. Lawrence D. et al. (2014) Long-term survival of ipilimumab-naive patients) with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. J Clin Oncol 32(Suppl. 5): abstract CRA9002.
32. Infante J. Powderly J. Burris H. Kittaneh M. Grice J. Smothers J. et al. (2013) Clinical and pharmacodynamic (PD) results of a phase 1 trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor. J Clin Oncol 31: abstract CRA3044.
33. Iwai Y. Ishida M. Tanaka Y. Okazaki T. Honjo T. Minato N. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-1 blockade. Proc Natl Acad Sci U S A 99: 12293–12297.
34. Iwai Y. Terawaki S. Honjo T. (2004) PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 17: 133–144.
35. Jandus C. Bioley G. Speiser D. Romero P. (2008) Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. Cancer Immunol Immunother 57: 1795–1805.
36. Khleif S. Lutzky J. Segal N. et al. (2013) MEDI4736, an anti-PD-L1 antibody with modified Fc domain: preclinical evaluation and early clinical results from a phase 1 study in patients with advanced solid tumors. Proceedings from the European Cancer Congress, 30 September, Amsterdam: abstract 802.
37. Konishi J. Yamazaki K. Azuma M. Kinoshita I. Dosaka-Akita H. Nishimura M. (2004) B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 10: 5094–5100.
38. Latchman Y. Wood C. Chernova T. Chaudhary D. Borde M. Chernova I. et al. (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2: 261–268.
39. Lebbé C. Weber J. Maio M. Neyns B. Harmankaya K. Hamid O. et al. (2013) Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials. J Clin Oncol 31: abstract CRA9053.
40. Mellor A. Sivakumar J. Chandler P. Smith K. Molina H. Mao D. et al. (2001) Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2: 64–68.
41. National Cancer Institute (2013) SEER 9 incidence & US mortality 1975–2010, all races, both sexes. Available at: http://seer.cancer.gov/statfacts/html/melan.html (accessed 26 March 2014).
42. Nishimura H. Honjo T. (2001) PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 22: 265–268.
43. Nishimura H. Masato N. Hiroshi H. Nagahiro M. Tasuku H. (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11: 141–151.
44. Nishimura H. Okazaki T. Tanaka Y. Nakatani K. Hara M. Matsumori A. et al. (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291: 319–322.
45. Ohigashi Y. Sho M. Yamada Y. Tsurui Y. Hamada K. Ikeda N. et al. (2005) Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11: 2947–2953.
46. Pardoll D. (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252–264.
47. Ribas A. Hodi F. Kefford R. Hamid O. Daud A. Wolchok J. et al. (2014) Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients with melanoma. J Clin Oncol 32(5 Suppl.): abstract LBA9000.
48. Salama A. Chitnis T. Imitola J. Ansari M. Akiba H. Tushima F. et al. (2003) Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 198: 71–78.
49. Salama A. Flaherty K. (2013) BRAF in melanoma: current strategies and future directions. Clinical Cancer Research 19: 4326–4334.
50. Schadendorf D. Hodi F. Robert C. Weber J. Margolin K. Hamid O. et al. (2013) Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Eur J Cancer 49(Suppl. 2): abstract 24LBA.
51. Spigel D. Gettinger S. Horn L. Herbst R. Gandhi L. Gordon M. et al. (2013) Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 31: CRA8008
52. Spranger S. Koblish H. Horton B. Scherle P. Newton R. Gajewski T. (2014) Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. J Immunother Cancer 2: 3.
53. Spranger S. Spaapen R. Zha Y. Williams J. Meng Y. Ha T. et al. (2013) Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci Transl Med 5: 200ra116.
54. Strome S. Dong H. Tamura H. Voss S. Flies D. Tamada K. et al. (2003) B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 63: 6501–6505.
55. Sznol M. Kluger H. Callahan M. Postow M. Gordon R. Segal N. et al. (2014) Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma. J Clin Oncol 32(5 Suppl.): LBA9003.
56. Sznol M. Kluger H. Hodi F. McDermott D. Carvajal R. Lawrence D. et al. (2013) Survival and long-term follow-up of safety and response in patients with advanced melanoma in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 31: CRA9006.
57. Sznol M. Powderly J. Smith D. Brahmer J. Drake C. McDermott D. et al. (2010) Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. J Clin Oncol 28: CRA2506.
58. Taube J. Anders R. Young G. Xu H. Sharma R. McMiller T. et al. (2012) Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4: 30036–30089.
59. Taube J. Klein A. Brahmer J. Xu H. Pan X. Kim J. et al. (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 8 April 8 2014 [Epub ahead of print].
60. Thompson R. Gillett M. Cheville J. Lohse C. Dong H. Webster W. et al. (2004) Costimulatory B7-H1 in renal cell carcinoma subjects: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 101: 17174–17179.
61. Thompson R. Gillett M. Cheville J. Lohse C. Dong H. Webster W. et al. (2005 a) Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 104: 2084–2091.
62. Thompson R. Webster W. Cheville J. Lohse C. Dong H. Leibovich B. et al. (2005 b) B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in subjects with renal cell carcinoma. Urology 66: 10–14.
63. Topalian S. Drake C. Pardoll D. (2012 a) Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24: 207–212.
64. Topalian S. Hodi F. Brahmer J. Gettinger S. Smith D. McDermott D. et al. (2012 b) Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med 366: 2443–2454.
65. Topalian S. Sznol M. McDermott D. Kluger H. Carvajal R. Sharfman W. et al. (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Cin Oncol 3 March 2014 [Epub ahead of print].
66. Tsushima F. Tanaka K. Otsuki N. Youngnak P. Iwai H. Omura K. et al. (2006) Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol 42: 268–274.
67. Weber J. Kudchadkar R. Yu B. Gallenstein D. Horak C. Inzunza H. et al. (2013) Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 34: 4311–4318.
68. Westin J. Chu F. Foglietta M. Rotem-Yehudar R. Neelapu S. (2010) Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. J Clin Oncol 28: TPS305.
69. Wolchok J. Kluger H. Callahan M. Postow M. Rizvi N. Lesokhin A. et al. (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369: 122–133.
70. World Health Organization (2013) Skin cancers. Available at: http://www.who.int/uv/faq/skincancer/en/index1.html (accessed 1 September, 2014).
71. Zheng Y. Zha Y. Driessens G. Locke F. Gajewski T. (2012) Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med 209: 2157–2163.